{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 407374808
| IUPAC_name = disodium [2,6-di(propan-2-yl)phenoxy]methyl phosphate<ref name=PubChem>{{cite web | author = PubChem Compound | date = | url = https://pubchem.ncbi.nlm.nih.gov/compound/3038497 | title = Compound Summary for CID 3038497): Fospropofol disodium | publisher = National Center for Biotechnology Information | location = Bethesda, Maryland | accessdate = 9 February 2017}}</ref>
| image = Fospropofol disodium.svg
<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|monograph|fospropofol}}
| licence_US = Fospropofol
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = B
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Schedule IV
| legal_status =
| dependency_liability = unknown
| routes_of_administration = [[Intravenous therapy|Intravenous]]
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = 98%<ref name=Eisai2009>{{cite web | author = Eisai Inc. |date = October 2009| url = http://www.eisai.com/package_inserts/Lusedra%20PI.pdf | title = LUSEDRA (fospropofol disodium) Injection | publisher = Eisai Inc. | location = Woodcliff Lake, New Jersey | accessdate = 2 August 2010}}</ref>
| metabolism = [[Liver|Hepatic]] [[Glucuronic acid|glucuronidation]]
| elimination_half-life = 0.81 hours<ref name=Eisai2009/>
| excretion = [[Kidney|Renal]]
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number =  258516-89-1
| CAS_supplemental = <br />{{CAS|258516-87-9}} (disodium salt)
| ATC_prefix = N01
| ATC_suffix =
| ATC_supplemental =
|  PubChem = 3038498
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 2302062
|  smiles = CC(C)c1cccc(c1OCOP(=O)(O)O)C(C)C
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C13H21O5P/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16)
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = QVNNONOFASOXQV-UHFFFAOYSA-N
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB06716
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = LZ257RZP7K
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04257
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201766
<!--Chemical data-->
| chemical_formula =
| C=13 | H=21 | O=5 | P=1
| molecular_weight = 332.243<ref name=PubChem/>
}}

'''Fospropofol''' ([[International nonproprietary name|INN]]<ref>{{cite web|title=Recommended INNs 2006, pt 56|url=http://www.who.int/entity/medicines/publications/druginformation/innlists/RL56.pdf?ua=1|website=World Heath Organisation|publisher=World Heath Organisation|accessdate=20 April 2016}}</ref>), often used as the disodium salt (trade name '''Lusedra'''<ref>{{cite web|url=http://www.asahq.org/news/asanews121508.htm |title=FDA Approves Fospropofol and Follows ASAs Labeling Recommendation |publisher=American Society of Anesthesiologists |date=2008-12-15 |accessdate=2011-03-30}}</ref>) is an [[Intravenous therapy|intravenous]]  [[sedative]]-[[hypnotic]] agent. It is currently approved for use in sedation of adult patients undergoing [[Laboratory diagnosis of bacteria|diagnostic]] or [[Therapy|therapeutic]] procedures such as [[endoscopy]].

==Clinical applications==
Several [[Water-soluble#Solubility of ionic compounds in water|water-soluble]] derivatives and [[prodrug]]s of the widely used intravenous anesthetic agent [[propofol]] have been developed, of which fospropofol has been found to be the most suitable for clinical development thus far.<ref>{{cite journal | last1 = Cooke | first1 = A | last2 = Anderson | first2 = A | last3 = Buchanan | first3 = K | last4 = Byford | first4 = A | last5 = Gemmell | first5 = D | last6 = Hamilton | first6 = N | last7 = McPhail | first7 = P | last8 = Miller | first8 = S | last9 = Sundaram | first9 = H | last10 = Vijn | first10 = P | title = Water-soluble propofol analogues with intravenous anaesthetic activity | journal = Bioorganic & Medicinal Chemistry Letters | volume = 11 | issue = 7 | pages = 927–30 | year = 2001 | pmid = 11294393 | doi=10.1016/S0960-894X(01)00088-9}}</ref><ref>{{cite journal | last1 = Bennett | first1 = DJ | last2 = Anderson | first2 = A | last3 = Buchanan | first3 = K | last4 = Byford | first4 = A | last5 = Cooke | first5 = A | last6 = Gemmell | first6 = DK | last7 = Hamilton | first7 = NM | last8 = Maidment | first8 = MS | last9 = McPhail | first9 = P | last10 = Stevenson | first10 = DFM | last11 = Sundaram | first11 = H | last12 = Vijn | first12 = P |title = Novel water soluble 2,6-dimethoxyphenyl ester derivatives with intravenous anaesthetic activity | journal = Bioorganic & Medicinal Chemistry Letters | volume = 13 | issue = 12 | pages = 1971–5 | year = 2003 | pmid = 12781176 | doi=10.1016/S0960-894X(03)00346-9}}</ref> Purported advantages of this water-soluble [[chemical compound]] include less pain at the site of intravenous administration, less potential for [[hyperlipidemia]] with long-term administration, and less chance for [[bacteremia]].{{Citation needed|date=August 2010}} Often, fospropofol is administered in conjunction with an opioid such as fentanyl.{{Citation needed|date=August 2010}}

==Clinical pharmacology==

===Mechanism of action===
Fospropofol is a prodrug of propofol; it is metabolized by [[alkaline phosphatase]]s to an [[active metabolite]], propofol.

===Pharmacodynamics===

===Pharmacokinetics===
Initial trial results on fospropofol pharmacokinetics were retracted by the investigators. As of 2011, new results were not available.<ref>{{cite journal|pmid=22345970|pmc=3275955 | doi=10.4103/0970-9185.92472 | volume=28|issue=1|title=Fospropofol: pharmacokinetics?|date=January 2012|journal=J Anaesthesiol Clin Pharmacol|pages=134–5|vauthors=Mahajan B, Kaushal S, Mahajan R }}</ref>

<!-- Hide potentially dangerous content based on retracted papers====Distribution====
Following the administration of fospropofol 12.5&nbsp;mg/kg (the maximum recommended dose) [[Unconsciousness|loss of consciousness]] takes about four minutes, compared to one arm-brain circulation time with propofol 2.5&nbsp;mg/kg (the maximum recommended dose).<ref name="pmid16928150">{{cite journal |author=Gan TJ |title=Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation |journal=Clin Pharmacokinet |volume=45 |issue=9 |pages=855–69 |year=2006 |pmid=16928150 |doi= 10.2165/00003088-200645090-00001|url=}}</ref>

====Metabolism====
Fospropofol is [[metabolism|metabolized]] in the [[liver]] by alkaline phosphatases to propofol, [[formaldehyde]], and [[phosphate]]. The hepatic metabolism of this prodrug to an active metabolite means that peak [[Blood serum|plasma]] levels of propofol after the administration of a bolus of fospropofol are lower than for an [[Equipotent molar ratio|equipotent]] dose of propofol and also that its clinical effect is more sustained.<ref>{{cite journal | last1 = Fechner | first1 = J | last2 = Schwilden | first2 = H | last3 = Schüttler | first3 = J | title = Pharmacokinetics and pharmacodynamics of GPI 15715 or fospropofol (Aquavan injection) - a water-soluble propofol prodrug | journal = Handbook of experimental pharmacology | volume = 182 | issue = 182 | pages = 253–66 | year = 2008 | pmid = 18175095 | doi = 10.1007/978-3-540-74806-9_12 | series = Handbook of Experimental Pharmacology | isbn = 978-3-540-72813-9 }}</ref><ref>{{cite journal | last1 = Shah | first1 = A | last2 = Mistry | first2 = B | last3 = Gibiansky | first3 = E | last4 = Gibiansky | first4 = L | title = Fospropofol assay: issues and impact on pharmacokinetic and pharmacodynamic evaluation | journal = [[European Journal of Anaesthesiology]] | volume = 26 | issue = 1 | pages = 81; discussion 81–2 | year = 2009 | pmid = 19122558 | doi = 10.1097/EJA.0b013e32831bc285 }}</ref> These features can be desirable for endoscopic procedures such as [[esophagogastroduodenoscopy]], [[colonoscopy]], [[bronchoscopy]], as well as for some surgical procedures done under [[local anesthesia|local]] or [[Regional anaesthesia|regional]] anesthesia.

Propofol is further metabolised to propofol [[glucuronide]] (34.8%) and [[Hydroquinone|quinol]] glucuronide.{{Citation needed|date=August 2010}} Formaldehyde is a known [[carcinogen]] but label information states that serum formaldehyde levels are similar to background levels. No long term studies have been done on the [[cancer]] risks.  The parent drug has a terminal [[Biological half-life|elimination half-life]] of 0.88+/-0.08 hours, which is non-renal.<ref>[http://www.fda.gov/cder/foi/label/2008/022244lbl.pdf ]{{dead link|date=March 2011}}</ref>

====Elimination==== hide potentially dangerous content-->

==Controlled substance==
Fospropofol is classified as a [[Controlled Substances Act#Schedule IV controlled substances|Schedule IV controlled substance]] in the United States' [[Controlled Substances Act]].<ref>"[http://edocket.access.gpo.gov/2009/pdf/E9-23971.pdf Schedule of Controlled Substances; Placement of Fospropofol into Schedule IV]," 74 Federal Register 192 (October 6, 2009), pp. 51234&ndash;51236.</ref>

==References==
{{Reflist}}

==Further reading==
*{{cite journal |vauthors=Fechner J, Ihmsen H, Hatterscheid D |title=Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion |journal=Anesthesiology |volume=101 |issue=3 |pages=626–39 |date=September 2004 |pmid=15329587 |doi= 10.1097/00000542-200409000-00011|url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0003-3022&volume=101&issue=3&spage=626 |displayauthors=etal  }}{{Retracted paper|{{PMID|22345970}}|intentional=yes}}
*{{cite journal |vauthors=Gibiansky E, Struys MM, Gibiansky L |title=AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 1): pharmacokinetics |journal=Anesthesiology |volume=103 |issue=4 |pages=718–29 |date=October 2005 |pmid=16192764 |doi= 10.1097/00000542-200510000-00010|url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0003-3022&volume=103&issue=4&spage=718 |displayauthors=etal  }}{{Retracted paper|{{PMID|22345970}}|intentional=yes}}
*{{cite journal |vauthors=Struys MM, Vanluchene AL, Gibiansky E |title=AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 2): pharmacodynamics and safety |journal=Anesthesiology |volume=103 |issue=4 |pages=730–43 |date=October 2005 |pmid=16192765 |doi= 10.1097/00000542-200510000-00011|url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0003-3022&volume=103&issue=4&spage=730 |displayauthors=etal  }}{{Retracted paper|{{PMID|22345970}}|intentional=yes}}
*Pruitt R, Cohen LB, Gibiansky E, et al. A randomized, open-label, multicenter, dose-ranging study of sedation with Aquavan injection (GPI 15714) during colonoscopy. Gastrointest Endosc 2005; 61: AB111.
*Lampotang S, Lizdas D, Gravenstein N, Yavas S (2006). University of Florida Department of Anesthesiology Virtual Anesthesia Machine Web site: {{cite web|url=http://vam.anest.ufl.edu/simulations/fospropofolpharmacokinetics.php |title=Web Simulation of Fospropofol Pharmacokinetics |publisher=University of Florida |date= |accessdate=2011-03-30}}

{{General anesthetics}}
{{Sedatives}}
{{GABAAR PAMs}}

[[Category:General anesthetics]]
[[Category:Sedatives]]
[[Category:Phenol ethers]]
[[Category:Prodrugs]]
[[Category:GABAA receptor positive allosteric modulators]]